Logotype for Celanese Corporation

Celanese (CE) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Celanese Corporation

Q2 2026 earnings summary

16 Oct, 2026

Executive summary

  • Q2 adjusted EPS was $2.45, with $140 million in free cash flow; FY 2026 adjusted EPS guidance of ~$6 and free cash flow guidance of $700 million-$800 million were reaffirmed.

  • Net sales rose 9% year-over-year to $2.75 billion, supported by higher pricing and favorable currency; Q2 earnings benefited from supply-chain agility and reliable delivery.

  • Strategic priorities include cost reductions, footprint optimization, divestitures and deleveraging, alongside growth in medical, electronics and AI infrastructure.

Financial highlights

  • Adjusted EBIT was $470 million, with a 17% margin; operating profit was $276 million, up 19% year-over-year.

  • Free cash flow was $140 million despite nearly $200 million of working-capital cash use; first-half working-capital cash use was nearly $300 million.

  • Engineered Materials adjusted EBIT was $234 million and Acetyl Chain adjusted EBIT was $321 million.

  • Q2 adjusted EPS was $2.45, the highest in nearly three years; net earnings attributable to shareholders were $125 million and diluted EPS was $1.13.

  • Gross profit rose to $618 million from $534 million year-over-year; operating margin increased to 10.0% from 9.1%.

Outlook and guidance

  • Q3 adjusted EPS guidance is $1.35-$1.75; Lanaken-related inventory absorption, lower Ibn Sina equity earnings and higher raw-material costs weigh on the outlook.

  • FY 2026 adjusted EPS guidance remains ~$6, and free cash flow guidance remains $700 million-$800 million; working capital is expected to be neutral to slightly positive for 2026.

  • Engineered Materials adjusted EBIT is expected to grow at a double-digit rate in 2026, closer to 15% than 10%, despite absorption, divestiture and equity-earnings headwinds.

  • Planned cost reductions include $80 million-$100 million in 2027 and $140 million-$180 million cumulatively across 2026-2027; further actions remain under consideration.

  • 2026 capital expenditures are projected at $300 million-$350 million; moderation in earnings is expected in H2 as supply normalizes and inventory actions continue.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Celanese